Ask the Heart Doctor: Aorta Disease Part 2
 
        This two part program answers all your questions about Aorta Disease and related disorders (Marfan syndrome, Ehlers Danlos, Loeys Dietz). Part 2 provides answers to questions about surgical treatments of aorta disease including when to operate, types of procedures and post-operative outcomes and concerns.
Part 1 answered questions about types of aorta disease; how this disease is diagnosed (including imaging and genetic testing); and medical management of aorta disease including monitoring, medications, blood pressure control, exercise and how to prevent progression.
Questions are answered by Aorta specialists Dr. Lars Svensson, Dr. Milind Desai and Dr. Vidyasagar Kalahasti.
Learn more about our Aorta Center.
Subscribe: Apple Podcasts | Podcast Addict | Buzzsprout | Spotify
Ask the Heart Doctor: Aorta Disease Part 2
Podcast Transcript
Announcer: 
Welcome  to Love Your Heart, brought to you by Cleveland Clinic's Sydell and Arnold  Miller Family Heart, Vascular & Thoracic Institute. These podcasts will  help you learn more about your heart, thoracic, and vascular systems, ways to  stay healthy, and information about diseases and treatment options. Enjoy.
Lars Svensson, MD, PhD:
Hello  again and I'm Lars Svensson, chairman of the Heart and Vascular and Thoracic  Institute, and with me today are Sagar Kalahasti and Milind Desai, experts in aortic  diseases.  We love talking about aortic  disease and we have a very big program here at the Cleveland Clinic. Last year,  we actually did, despite COVID, 1,381 aortic operations. So by far the biggest  in the world, and we have a very active program and we see a lot of  emergencies, urgent patients needing surgery, and also elective operations. In  fact, as of December last year, we had done 1,113 modified reimplantations of  the aortic valve. And I was just looking at data this morning with 214 patients  with connective tissue disorders, we have not had a death after that operation,  and there is no significant difference in our hands as far as the durability of  these reimplantation, operations, and preserving the aortic valve between  connective tissue disorders and non connective tissue disorders.
Lars Svensson, MD, PhD:
That's  hot off the press. I saw it this morning and that's in 214 patients, so really  good results. For the general population without connective tissue disorders,  we're also running at 97% freedom from reoperation, 10 years after surgery, and  for elective surgery operations, we've only had one death out of 860, so about  a 0.1%, one in a thousand risk of death, for a very complicated operation that  only a few of us do in the country. So we're going to start off by talking  about what size should you operate on a patient and do the symptoms make any  influence on this? What about body size? Does it make a difference for aortic  root bicuspid valves, age, family history, or family history of aortic  dissection? I'll start off with you and Milind, and a lot of issues in that  decision-making.
Milind Desai, MD:
This  is a very interesting question, and the answer is not a one size fits all  answer. The first and foremost thing I'm going to say and emphasize as Dr.  Svensson mentioned, experience is key, having the right team of folks taking  care of you is probably more important than anything else, especially more  important than any other disease, the synchrony of how the teams operate. So  having said that, the thresholds are... Yes, there is nuance decision-making  about thresholds. Most people are going to be hearing numbers, five centimeters  or higher, five and a half centimeters or higher, these are fairly common  numbers in terms of thresholds you're going to be hearing. But there's  substantial nuance decision-making and thought process behind how we send  patients for an operation. Clearly you are reaching 5.5 centimeters, that's a  no-brainer. 
Milind Desai, MD:
But  what about, if you are somebody who's barely five foot tall and your aorta is  4.8 centimeters in the ascending portion, do we have the same threshold versus  somebody who is six foot one? The answer is clearly no. So very often,  precision of measurement is crucial and once we are precise in measurement, we  often index your aortic area to your height. And we have multiple publications  that have shown that, that adds incremental value beyond just simple dimension  measurements. So a ratio, if you're aortic area to height ratio happens to be  more than 10, then data have shown, large scale data have shown that you are  better off getting operated at an experienced center with such stellar  outcomes, preemptively, before your aorta reaches five or five and a half  centimeters.
Milind Desai, MD:
The  other important group is those with familial predisposition, especially those  with Marfans or those with Ehlers-Danlos or any familial diseases, Loeys-Dietz  syndrome, the threshold needs to be much lower than five centimeters, and it  often is if you have a malignant family history of multiple family members  dying of a dissection. Then we are going to not wait for the standard  threshold, we would recommend getting operated earlier.
Milind Desai, MD:
The  other group is patients with valve disease who need to have a heart surgical  operation, then the threshold that we use is 4.5 centimeters. So if you are  undergoing aortic valve surgery or mitral valve surgery, if you're ascending  aorta is more than four and a half centimeters, then we would recommend getting  the aorta replaced at the time of that operation. So it is not one size fits  all, there is nuanced thought processes, your height related, malignancy of  your family related, whether or not you need concomitant history, and also at  an experienced center like ours, we are more inclined to initiate the operation  conversation once you reach at a five centimeter threshold. There are plenty of  patients who have careers that are not conducive to walking around with a  significantly aneurysmal aorta. So in those patients, we would recommend an  earlier operation, especially if done by an experienced center, by an  experienced surgeon.
Lars Svensson, MD, PhD:
So  Sagar, would you like to add to that and particular in relation to age, the  size of aortic root versus the ascending aorta and patients with bicuspid  valves?
Sagar Kalahasti, MD:
Thanks  Dr. Svensson. In bicuspid valve patients, again, there are certain phenotypes,  particularly with the aortic root being involved or aortic root being  aneurysmal. I think data has shown that operating that smaller sizes,  particularly in conjunction if they have aortic valve regurgitation, definitely  makes a significant amount of difference for those patients. In other  conditions, such as in Marfans or Loeys-Dietz, of course we would operate at  much smaller sizes, more into the four to 4.3 centimeter range. And in Mafans again,  I think the thresholds will continue to come down. I think current  recommendations would say about five centimeters, but probably less than that,  if there is any family history of dissection or smaller sizes in those family  members. So I think that's important to keep in mind.
Lars Svensson, MD, PhD:
So  we looked at just over 1,100 of our patients with bicuspid valves and an aorta  more than 4.7 centimeters in size, and we found that the risk of aortic  dissection increases at about five centimeters diameter for the aortic root and  for the ascending aorta about 5.2. But we found the best predictor of  dissection occurring was the ratio. In other words, Milind mentioned a cross  sectional area divided by the patient's height in meters when that was above  10. And the other important point is, when we follow these patients out to 10  years, the bigger the size they started off with, the more likely they were  eventually to need an operation, so that also comes into our thinking.
Lars Svensson, MD, PhD:
We  also consider what's happening with the bicuspid valve. Is it a valve that's  diseased? Is it a valve that maybe will last a few more years and we can use a  biological valve and that at the time of surgery and the replacement? So that  also comes in to our thinking. So in 2010, I was involved in writing the  Thoracic Aorta Guidelines sponsored by the American Heart Association and  American College of Cardiology and Surgical Societies. And we recommended  surgery at about five centimeters for most patients with bicuspid valves and  Marfan syndrome, but also using the ratio, older patients who don't have any  risk factors and ascending aorta certainly a larger size, can be watched.
Lars Svensson, MD, PhD:
Then  at later, the valve guidelines came out and recommended 5.5 centimeters, which  resulted in a lot of confusion. And the two groups then got together, and at  that stage, we had published our series on bicuspid valves and the  recommendations then came out that were modified and that are in the latest  valve guidelines now also. So the cutoff is five centimeters in diameter,  particularly if their root is involved and the operation can be done at a  center of excellence, then it's reasonable to operate, and that's more or less  what we use.
Lars Svensson, MD, PhD:
If  there're other risk factors, particularly family history of aortic dissection,  then we operate at a smaller size. Now this is in a sense of prophylactic  operation, we do before aortic dissection happens, because if an aortic  dissection happens, then that usually results, first of all, in a very high  mortality rate. With a dissection there's new research confirming again, that  the risk of death is 1% per hour in patients who have aortic dissection, if  they don't die immediately and they're awaiting surgery. And then on top of  that, if they have a successful operation and the mortality rate for an  operation for acute dissection varies from round about 5 to 6% here at the Cleveland  Clinic, but in the IRAD database, that used to be up to 21%. And then if people  get through that, they have typically multiple operations after that. So it's  very important to have the prophylactic operation if the aortas enlarge.
Lars Svensson, MD, PhD:
So  the obvious question is, well, does it prevent aortic dissection? So we looked  at some 660 of our patients that had roots surgery, not all of them  reimplantations and the risk of developing a later dissection, typically in the  descending aorta, so area not operated on was 1.4% and the most important risk  factor for that was Marfan syndrome. So it does reduce the risk of subsequent  dissection and in patients who don't have a connective tissue disorder, they  can go back to completely normal lifestyle. And even in the Marfan syndrome, or  Ehlers-Danlos patients, or Loeys-Dietz patients, depending on what the activity  they're planning to do, they can live a normal lifestyle. And in fact, our data  shows a normal life expectancy in those patients once they've undergone their  operations.
Lars Svensson, MD, PhD:
So  there are some surgical operation questions. So I'm going to ask onto those  directly, so what is surgery and what is available for the ascending aorta? So  if it's only the ascending aorta and not involving the aortic valve, we will  typically do what we call a minimal invasive J-incision. And so that's an  incision about three centimeters long in the upper chest, and we make it so  like a trapdoor, we go in and we put in a plastic tube, it's actually a  polyester, it used to be called Dacron, and we replace the aorta with that, we  sew into position and we know that the results of that are very good.
Lars Svensson, MD, PhD:
In  fact, if you look at our patients with bicuspid valves who had aortic replacements,  the risk of another aortic operation within 15 years of the original operation,  it's only 2%. That's separate from the aortic valve, the aortic valve as a  separate issue. So what if the aortic valve bicuspid valve is involved? Well,  then it depends what the problem is with a bicuspid valve, and just to segue a  bit to my cardiology colleagues here, in a bicuspid valve, when do you operate  for a valve that's narrowed down. I'll ask that of Milind and for a leaking  valve, I'll ask Sagar to answer that question. Milind, a stenotic valve.
Milind Desai, MD:
As  Dr. Svensson mentioned, a bicuspid aortic valve, it is where essentially there  are two leaflets, two flappers rather than three, and this tends to be an  inherited situation. So there's two... Typically what the natural history of a  bicuspid aortic valve is, it progressively gets calcified or calcium buildup  happens, and when patients reach typically in the late fifties, early sixties,  it gets severely narrowed to a point where it then is impeding the flow of  blood out of the heart, which essentially results in symptoms. Symptoms often  involve shortness of breath, chest pain, dizziness, occasionally passing out,  and if you leave it untreated, then it results in a heart failure like  symptoms. So once the aortic valve gets narrowed to a severe level, so there's  cutoffs, there's thresholds, there's severity, it could be an absolute number  of less than one centimeter square or 0.7 centimeter square would be critical.  You can index it to height, given the discrepancies in various heights. You can  index it to height, either way, once it reaches severe in terms of valve area.
Milind Desai, MD:
There's  another way of ascertaining severities through gradient. Gradient is the  pressure difference between the aorta and the heart, because of a severely  narrowed aortic valve. Once these thresholds reach beyond severe it's typically  when we start thinking about an operation, especially in the context of  symptoms. There's emerging data now that waiting for symptoms may be waiting a  bit too long, so we are developing new biomarkers like blood tests, like BNP,  strain values, et cetera. These things can help guide decision-making about  timing of an operation, but once it clearly reaches severe, in terms of  narrowing, it's the time for you to operate. Now, there may be certain  scenarios where we may operate in a moderately narrowed valve. If the patient  is undergoing surgery for other reasons, like bypass or mitral valve disease or  something else, then we may operate, replace that aortic valve, even if it is  moderately narrowed. But generally, we wait for severe valve disease, severe  stenosis, severe narrowing of the aortic valve before aorta pairing or  replacing.
Lars Svensson, MD, PhD:
Sagar,  what about a regurgitant valve, leaking valve?
Sagar Kalahasti, MD:
Thanks  Dr. Svensson. Just like Milind had mentioned, aortic valve regurgitation also,  there are parameters with regards to looking at the severity of the valve  regurgitation dealing with mild, moderate, and severe, and if the valve reaches  severe range then in general, aortic valve intervention is recommended. Now  keep in mind with aortic valve regurgitation, there's a lot of leaking across  the valve and that leak is going back into the ventricle. So over time, the ventricle  has to enlarge or dilate to accommodate all the blood that's leaking back. And  as Milind has mentioned, sometimes even before patients develop symptoms,  symptoms can be very vague in different patients. Sometimes it can just be  tiredness, or shortness of breath, or sometimes advanced stages, you could  actually get swelling of your legs, like with heart failure. So there is more  impetus now to prevent the ventricle reaching the point of becoming  dysfunctional, and echocardiogram is very helpful in looking at the size of the  ventricle and sometimes intervening before the ventricle reaches dysfunction.
Sagar Kalahasti, MD:
In  the setting of aortic valve regurgitation, I think it's a very good idea. Just  like Milind mentioned, if you're undergoing surgery for aortic, if the aorta is  enlarged and you're going to fix the aorta, then I think addressing the aortic  valve regurgitation is also important. Some of the caveats or differences with  the stenosis is that, aortic valves which are leaking, can actually be  repaired, and Dr. Svensson has excellent experience in looking at the aortic  valve repair as an option, instead of replacement and that's another important  factor to look in, in the aortic valve regurgitation.
Lars Svensson, MD, PhD:
All  right. Another surgical question is, when is the reimplantation operation  appropriate? So we do this operation when the valve is not calcified and the  aortic root is enlarged, and we do that for both bicuspid and a three leaflet  valves, the normal valves. We reimplant those within a plastic tube, that's why  it's called a reimplantation operation. And as I mentioned earlier, the results  are really excellent with that operation. The way we've modified it, it's very  predictable, really excellent outcomes long-term. And so when it comes to the  reimplantation operation, if there's not much aortic valve regurgitation, like  two patients I saw today, I will tell them the likelihood is 95%, we can  reimplant that valve in a new tube and keep their own valves. If there's severe  regurgitation, the regional three or 4%, a three and four rating, so that's out  of a score four, and the valve is a three leaflet valve, then it goes down to  somewhere in the region of 85, 90%, we can keep the valve, and that's dependent  of the big holes and the leaflets or not.
Lars Svensson, MD, PhD:
For  bicuspid valves, we have also the option of a remodeling operation or a direct  repair of the bicuspid valve and replacing the ascending aorta, which has also  very good operation. We've actually looked recently at whether it makes a  difference, replacing the ascending aorta at the same time with a bicuspid  valve repair or only doing a repair, and the results are about equivalent for  bicuspid valves. And when there's a root involvement, we've got what's called a  remodeling operation or the reimplantation operation, depending on the  situation that we find. So those are the operations.
Lars Svensson, MD, PhD:
Do  we do minimally invasive operations for the root operations? So I developed the  J-incision in the mid nineties and I pushed it to the limits. We were doing the  so-called arch elephant trunk procedures with that, I did a lot of  reimplantations, root remodelings with that. But I must admit, I've backed off  on that because these are already complicated operations, and it's very helpful  to have a good view of the heart, to make sure the heart is well-protected  during these operations. So I don't any longer do reimplantations as a  minimally invasive operation for those reasons, I think we can get a better  long-term result with a full sternotomy as we call it.
Lars Svensson, MD, PhD:
So  there are questions about FDA approval for the peers devices and various types  of braces for aortic valve repairs. So we've actually got a series of some  4,600 aortic valve repairs, not necessarily with aneurysms, although when we  brace the root, we have better results. And we feel the results are so good,  and any of these devices introduce more complexity and potential problems. And  for example, with wrapping the aorta, for example in Marfans, what we see is  when patients have had that done, it's a bit like a balloon. And as a child, if  you took a balloon and squeezed it, what happened? The other two ends popped  out, and that's what happens when people put wraps around the aorta, other  parts starts growing.
Lars Svensson, MD, PhD:
So  the operations are so safe nowadays, and there's no reason to do wraps and so  on when we can do a much more effective operation with better long-term  durability. So for our ascending aortic replacements in patients with bicuspid  valves, the risk of death was 0.25%, quarter of a percent. And we know, as I  mentioned earlier, that that's a very durable operation and so we have not  tried using these other devices, which can cause scarring and other problems  over time.
Lars Svensson, MD, PhD:
So  I'm just going to touch on a couple of other topics, which is endovascular  treatment of the ascending aorta. That is a experimental procedure that can be  sometimes used in very high risk patients when their localized tears or  dissection of the ascending aorta, particularly in elderly patients, when other  options aren't available, we are investigating that. But at this stage, that is  not a treatment that we would recommend as an alternative for any of the very  safe procedures we do.
Lars Svensson, MD, PhD:
What  about patients with aortic enlargement who need TAVR? We would not recommend a  TAVR, anybody who's aorta is more than 4.5 centimeters just as we do with  surgery, because there's a very high risk of aortic dissection with TAVR, an  enlarged aorta. What about, does all ascending aortic aneurysms require open  surgery? I think I've answered that from the point of view of endovascular and  yes, for 99% of patients, the ascending aorta replacement during an open  operation, particularly if it's appropriate, min invasive operation is a very  safe operation. So how long does aortic surgery last? In the bicuspid valves,  as I said, there's a 2% risk of another operation within 15 years. In patients  who have giant cell arteritis, there is a slightly higher risk over time, so we  tend to do more extensive repairs in the patients with giant cell arteritis.
Lars Svensson, MD, PhD:
So  many inpatients with aortic dissection, we are tending to become more  aggressive in the operation and particular replacing the ascending aorta and  arch, even with stent grafts, so that a second operation through the left chest  or with a stent is easier to do. We talked about the modified reimplantation  David Procedure, and as I said, we have about a three in a 100 failure rate at  10 years, my guess is, it's going to be about a five, 6% at 20 years. The  results are really looking good with the way we've modified the operation and  narrowing down the left ventricular outflow tract with a Hegar's dilator that's  normal for the patient's size and height.
Lars Svensson, MD, PhD:
How  about biologic valves? Biologic valves durability is very dependent on the age  of the person. The way we've looked at it, and you can look it up in the  literature is, we've looked at the risk, our reoperation within 12 years of  surgery. So the younger the person is, the greater the risk. On the other hand,  in the elderly, the biological valves hold up very well. And there's always an  option of doing a TAVR in those valves over time. Having said that, in patients  who have aortic valve replacement at the Cleveland Clinic, there is no  difference in the risk of death for a first time operation, or a second or  third operation, what we call a reoperation, and that's been the case since  2010.
Lars Svensson, MD, PhD:
So  at the Cleveland Clinic, there is no difference in risk between those  operations. We talked about life expectancy, but just to reiterate, inpatients  who have prophylactic operations and who have aneurysms replaced before aortic  dissection, the life expectancy is normal and we've got several studies that  have shown that, including with a valve replacement, where the aortic  dissection, then it's very dependent on the blood pressure control after the  procedure. All right, so there are a couple of other question, how often is a  pacemaker needed after valve surgery? I'll start off Sagar with you, what about  pacemakers after aortic surgery?
Sagar Kalahasti, MD:
So  in general, for most patients with aortic valve replacement, they wouldn't need  a pacemaker, unless they have a prior conduction abnormality within their  rhythm, something like a left bundle branch block or a right bundle branch  block. if they have that going into surgery, then a very small number of  patients may require a pacemaker after aortic valve replacement surgery. But in  general, for most patients, pacemaker is usually not necessary.
Lars Svensson, MD, PhD:
So  usually we quote about a 1 or 2% risk of a pacemaker with a open aortic valve  replacement. It runs at about eight to 10% for TAVR, although our team has had  better results than that. For a reimplantation operation, we usually run at  about 2 to 3% risk of a pacemaker after that type of operation. So let me turn  to you Milind, as we wind things down here. What medications do you like to put  patients on after aorta surgery or valve surgery and how often would you  monitor patients, whether that's with the MRI, CAT scans or Echos, what are  your thoughts on that?
Milind Desai, MD:
Thank  you so much. So in terms of post operative medications, we have a preferential  bias towards keeping patients on beta blockers, because a lot of these patients  have concomitant cardiovascular disease, LVH et cetera, and it helps with the  blood pressure, it helps with the heart rate, it helps with postoperative AFIB,  et cetera. So it is something that we would typically continue these patients  on, at least in a low dose. Now, a lot of other post operative medications  would be driven by what other concomitant conditions they have, especially if  they have cholesterol problems. If they have hypertension that requires  multiple medical therapies, then the bias would be for the angiotensin receptor  family of drugs. Now, in terms of follow up, there is... Clearly depending upon  the extent of the disease that the patient had, and the extent of the disease  that the patient had fixed, is what is going to drive the follow up regimen.
Milind Desai, MD:
So  for example, if you have somebody with a dissection, that extends from the  ascending aorta all the way to the groin, and we have fixed the first part of  the disease by open-heart surgery, these patients will have a different and a  lot more regimented, much more frequent follow-up schemata than somebody who  just had a small area of ascending aorta that needed replacement and everything  else is normal.
Milind Desai, MD:
Now,  having said that, it is important for... An aortic patient, is a lifelong  patient. Aorta is a lifelong disease, so even if we have fixed you, ostensibly  fixed you, you need to follow up. We like to see patients at least once a year  and do their imaging. Now, if the valve is involved, then you need to also  image their valves using echocardiography and/or occasionally MRI. If it's the  aorta, then a tomographic scan is important. If it is a dissected aorta, that  has had stents placed, then you need a special type of CAT scan to look for  what is called endoleak. So it is again, not a one size fits all. The most  important message that I would say is, you are a lifelong patient and every  care is individualized and should be discussed with your expert provider.
Lars Svensson, MD, PhD:
So  Sagar one last question for you. What do you do for patients who have  occasional loss of vision who have had a aortic operation, and this I think is  particularly relevant to mechanical valves, what do you do for those patients?
Sagar Kalahasti, MD:
Thank  Dr. Svensson. I think anti-inflammatory medications like aspirin, is routinely  used in patients with both valve replacements, I'm talking more biological  valve replacements or valve repairs. And of course for mechanical valve  patients, you need to be on blood thinners, particularly Coumadin is the only  one that's currently approved. So if somebody has a loss of vision, despite  being on these medications, I think it's important that they're evaluated by  neurology to make sure there is no other reasons, but I think being on aspirin  is the important thing for patients with biological valves, or with the valve  repairs.
Lars Svensson, MD, PhD:
All  right. Just a couple of final points. One question was, how often do patients  who've had modified reimplantation developing leaking valves? As I've said  before, the risk of reoperation is about 3% within 10 years of surgery. I  happened to be looking at some of our data on echocardiograms today. So about  30% of patients who have one plus or less, which is our standard for leaving  the operating room after reimplantation operation, about 30% will develop a  slight valve leak over time. Usually that occurs in the first year or two, but  then after that it's stable over time, doesn't seem to get worse. So about 30%  will have one or two plus regurgitation. Now, if it progresses, then there is  the risk of reoperation, which turns out to being pretty rare in our series of  patients. In fact, the one series I was looking at today, 22 patients needed  another operation for just under 1000 patients, and six of those were patients  who had Marfan syndrome.
Lars Svensson, MD, PhD:
But  as I said, we found no difference between patients who had Marfan syndrome, and  those who did not have Marfan syndrome, that is somewhat influenced, that in  patients with bicuspid valves who have reimplantation, they are more prone over  time to get calcification of those valves, because they are abnormal or leakage  of those valves, so that does influence the outcomes. We know that long-term  bicuspid valves do have a slightly higher rate of failure. In our experience,  when we looked at 728 patients, the risk was 9%. So in other words would recall  freedom from reoperation at 10 years was 91%. So the results are very good with  repairs in this group of patients. I hope you've found this useful, it's been a  long session, but we've tried to cover all your questions and group them  together. Thank you very much, and it was a pleasure speaking to you.
Milind Desai, MD:
Thank  you.
Sagar Kalahasti, MD:
Thank  you so much for the opportunity.
Announcer: 
Thank  you for listening. We hope you enjoyed the podcast. We welcome your comments  and feedback. Please contact us at heart@ccf.org. Like what you heard?  Subscribe wherever you get your podcasts, or listen at  clevelandclinic.org/loveyourheartpodcast.
 
						
					
					Love Your Heart
A Cleveland Clinic podcast to help you learn more about heart and vascular disease and conditions affecting your chest. We explore prevention, diagnostic tests, medical and surgical treatments, new innovations and more.
 
						 
						